
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CSCI | Toronto | CAD | Real-time | |
CSCI | NASDAQ | USD | Real-time | |
0UGB | London | CAD | Real-time | |
ET8 | Frankfurt | EUR | Delayed |
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Gilles R. Gagnon | 71 | 2007 | Director |
Hartmut Michel | - | - | Member of the Scientific Advisory Board |
Rene De Frydman | - | - | Member of the Scientific Advisory Board |
Marcel Verheij | - | - | Member of the Scientific Advisory Board |
Gerald Batist | - | - | Member of the Scientific Advisory Board |
Alan H. DeCherney | - | - | Member of the Scientific Advisory Board |
Frans M. J. Debruyne | - | - | Member of the Scientific Advisory Board |
Daniel Douglas Von Hoff | 77 | 2005 | Member of the Scientific Advisory Board |
Klaus H. R. Diedrich | - | - | Member of the Scientific Advisory Board |
Ulf R. Rapp | - | - | Member of the Scientific Advisory Board |
Ulrich Kosciessa | - | 2024 | Independent Director |
Anthony J. Giovinazzo | 68 | 2025 | Independent Director |
David Spear | - | 2025 | Independent Director |
Ronald W. Miller | - | 2024 | Independent Director |
Robert A. Seager | - | 2025 | Independent Director |
Peter Harry Puccetti | - | 2025 | Independent Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review